All In MedTech

Device Trial Radar · NCT07949370

A Phase 2 Study of Dynamic BH3 Profiling (DBP) Guided Combination Therapy in Subjects With R/R AML

A Phase 2 Study Using the Dynamic BH3 Profiling Assay to Guide Venetoclax-Based Combination Therapy for Participants With Relapsed or Refractory Acute Myeloid Leukemia

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Mar 6, 2027

Primary completion

Dec 31, 2029

Study completion Jul 31, 2030

Sponsor

Lead sponsor
Dana-Farber Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AbbVie; National Cancer Institute (NCI); Stemline Therapeutics, Inc.; Syndax Pharmaceuticals
First posted
Nov 19, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the feasibility and efficacy of using the dynamic BH3 profiling (DBP) assay as a biomarker to guide venetoclax-based combination therapy for participants with relapsed or refractory acute myeloid leukemia (AML).

Conditions

  • Relapsed or Refractory Acute Myeloid Leukemia (AML)

Interventions

  • Dynamic BH3 ProfilingDevice

    Dynamic BH3 Profiling is performed on myeloblasts obtained from a bone marrow aspirate to assess drug-induced apoptotic priming, using cytochrome c retention as the assay readout. The report evaluates venetoclax-based combinations and includes comparisons that are intra-patient and inter-patient (against a pooled historical dataset). The Protocol Tumor Board reviews the DBP report, screening findings, drug-specific eligibility, and patient and disease history to determine treatment assignment. The protocol defines feasibility as successful assay performance and delivery of the DBP report within five days of sample receipt.

  • VenetoclaxDrug

    Venetoclax is a selective BCL-2 inhibitor administered as a component of every protocol treatment regimen. Target dose and duration are specific to each treatment regimen. Doses may be reduced when given with azoles or other interacting agents, and treatment may be held for clinically significant tumor lysis syndrome.

  • CytarabineDrug

    Cytarabine will be tested in combination with venetoclax at different dosing strategies. Low-dose cytarabine will be combined with venetoclax in Arm 1. It is also administered as part of the venetoclax-cladribine-based regimen in Arm 6, at low or mid-intensity dosing based on age and fitness, and will be age-adjusted for safety.

  • GilteritinibDrug

    Gilteritinib is administered in combination with venetoclax to participants assigned to Treatment 2 based on DBP findings and confirmation of regimen-specific eligibility.

  • Azacitidine (AZA)Drug

    Azacitidine is administered with venetoclax and tagraxofusp in Arm 3 and with venetoclax and revumenib in Arm 5. Dosing of azacitidine is standard at 75 mg/m² daily on Days 1-7.

  • TagraxofuspDrug

    Tagraxofusp is administered in combination with venetoclax and azacitidine to participants assigned to Treatment 3 based on DBP findings and confirmation of regimen-specific eligibility.

  • DecitabineDrug

    Decitabine is administered in combination with venetoclax to participants assigned to Treatment 4 based on DBP findings and confirmation of regimen-specific eligibility.

  • RevumenibDrug

    Revumenib is administered orally and in combination with venetoclax and azacitidine to participants assigned to Treatment 3 based on DBP findings and confirmation of regimen-specific eligibility.

  • Cladribine (CLAD)Drug

    Cladribine is administered with venetoclax and low- or mid-intensity cytarabine in a combination regimen. ladribine is administered at 5 mg/m² daily on Days 1-5 of a 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Feasibility Rate of Dynamic BH3 Profiling (DBP)Time frame: Within 5 days of receipt of a viable sample.
  2. Overall Response Rate (ORR)Time frame: Assessed at the end of Cycles 1, 2, and 4 (each cycle is 28 days), and every 3 cycles thereafter for up to 1 year, with an end-of-treatment assessment (up to 2 years; up to 3 months or 2 cycles for the cladribine/venetoclax arm).
  3. Reasons for Unsuccessful Assignment to DBP-Guided TherapyTime frame: During the screening period (up to 21 days).

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.